StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the stock. Several other research analysts also recently commented on the company. Needham & Company LLC reduced their price objective on OncoCyte from $9.00 to $4.25 and […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the stock. OCX has been the topic of a number of other reports. Benchmark reduced their price target on shares of OncoCyte from $9.00 to $5.00 and set […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Monday. The brokerage issued a sell rating on the stock. Other analysts have also recently issued research reports about the company. Needham & Company LLC dropped their target price on OncoCyte from $9.00 to $4.25 and set a buy […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC dropped their target price on shares of OncoCyte from $9.00 to $4.25 and set a buy rating for the company in a […]
StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Monday morning. The brokerage issued a sell rating on the stock. Separately, Needham & Company LLC decreased their price objective on shares of OncoCyte from $9.00 to $4.25 and set a buy rating on the stock in a […]